Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients With Previously Untreated High Grade Myelodysplastic Syndromes

NCT03564873•University of Colorado, Denver

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

High Grade Myelodysplastic Syndromes

Interventions

Omacetaxine

Azacitidine

+2 more

Locations

United States

Locations (1)

Universtiy of Colorado Denver

Aurora, Colorado, United States

Key Dates

Start Date

September 17, 2018

Primary Completion Date

October 7, 2025

Completion Date

June 1, 2027

Last Updated

December 11, 2025

Sponsors

Lead Sponsor

University of Colorado, Denver

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions